Dimitrios P Kontoyiannis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6248309/publications.pdf

Version: 2024-02-01

190 papers	21,906 citations	17776 65 h-index	10679 143 g-index
198 all docs	198 docs citations	198 times ranked	15197 citing authors

#	Article	IF	Citations
1	Investigational Antifungal Agents for Invasive Mycoses: A Clinical Perspective. Clinical Infectious Diseases, 2022, 75, 534-544.	2.9	47
2	Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata. Microbiology Spectrum, 2022, 10, e0183721.	1.2	0
3	Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis. Frontiers in Immunology, 2022, 13, 838344.	2.2	19
4	Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model. MSphere, 2022, 7, e0081721.	1.3	16
5	Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clinical Infectious Diseases, 2022, 75, 1503-1510.	2.9	16
6	Are Unique Regional Factors the Missing Link in Indiaâ€™s COVID-19-Associated Mucormycosis Crisis?. MBio, 2022, 13, e0047322.	1.8	15
7	Invasive mould infections in patients from floodwater- damaged areas after hurricane Harvey â€“ a closer look at an immunocompromised cancer patient population. Journal of Infection, 2022, , .	1.7	5
8	Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients. Frontiers in Cellular and Infection Microbiology, 2022, 12, 848580.	1.8	2
9	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. Open Forum Infectious Diseases, 2022, 9, .	0.4	25
10	Taking a Closer Look: Clinical and Histopathological Characteristics of Culture-Positive versus Culture-Negative Pulmonary Mucormycosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 380.	1.5	3
11	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (nonâ€fumigatus): A multicentre, nonâ€interventional registry study. Mycoses, 2022, 65, 186-198.	1.8	7
12	Drosophila melanogaster as a Rapid and Reliable In Vivo Infection Model to Study the Emerging Yeast Pathogen Candida auris. Methods in Molecular Biology, 2022, , 299-316.	0.4	2
13	Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clinical Infectious Diseases, 2021, 72, 1755-1763.	2.9	48
14	Pharmacological serum concentrations of epinephrine and norepinephrine do not affect growth rate, morphogenesis, stress tolerance, and virulence of Candida albicans. Medical Mycology, 2021, 59, 102-105.	0.3	0
15	Disseminated cryptococcosis and antiâ€granulocyteâ€macrophage colonyâ€stimulating factor autoantibodies: An underappreciated association. Mycoses, 2021, 64, 576-582.	1.8	16
16	Breakthrough Mucormycosis Developing on Mucorales-Active Antifungals Portrays a Poor Prognosis in Patients with Hematologic Cancer. Journal of Fungi (Basel, Switzerland), 2021, 7, 217.	1.5	17
17	EGF-mediated suppression of cell extrusion during mucosal damage attenuates opportunistic fungal invasion. Cell Reports, 2021, 34, 108896.	2.9	9
18	Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer, 2021, 127, 2489-2499.	2.0	34

#	Article	IF	Citations
19	Environmental Candida auris and the Global Warming Emergence Hypothesis. MBio, 2021, 12, .	1.8	62
20	Aspergillus terreus Species Complex. Clinical Microbiology Reviews, 2021, 34, e0031120.	5.7	23
21	Resistance to Antifungal Drugs. Infectious Disease Clinics of North America, 2021, 35, 279-311.	1.9	36
22	Effect of high-dose posaconazole on serum levels in adult patients with hematologic malignancy. Antimicrobial Agents and Chemotherapy, 2021, 65, e0123021.	1.4	1
23	Fungal Infections in Cancer Patients. , 2021, , 792-802.		1
24	Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections. Journal of Fungi (Basel, Switzerland), 2021, 7, 17.	1.5	36
25	Cat Scratch Disease as a Mimicker of Malignancy. Open Forum Infectious Diseases, 2021, 8, ofab500.	0.4	5
26	Infectious complications among patients with AML treated with immune checkpoint inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	3
27	991. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Mortality, Infection Severity, and Fungal Clearance in an Immunosuppressed Murine Model of Invasive Pulmonary Mucormycosis. Open Forum Infectious Diseases, 2021, 8, S586-S586.	0.4	1
28	Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clinical Infectious Diseases, 2020, 71, 63-71.	2.9	61
29	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020, 71, 1367-1376.	2.9	1,429
30	Live imaging and quantitative analysis of Aspergillus fumigatus growth and morphology during inter-microbial interaction with Pseudomonas aeruginosa. Virulence, 2020, 11, 1329-1336.	1.8	6
31	How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood, 2020, 136, 2741-2753.	0.6	6
32	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27â€“30, 2018, Big Sky, Montana, a proposed global research agenda. Medical Mycology, 2020, 58, 569-578.	0.3	1
33	Nonâ€Aspergillus invasive mould infections in patients treated with ibrutinib. Mycoses, 2020, 63, 787-793.	1.8	14
34	Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy With Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model. Journal of Infectious Diseases, 2020, 222, 989-994.	1.9	19
35	European confederation of medical mycology expert consultâ€"An ECMM excellence center initiative. Mycoses, 2020, 63, 566-572.	1.8	8
36	How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions. Clinical Infectious Diseases, 2020, 71, 685-692.	2.9	15

#	Article	IF	Citations
37	Tornadic Shear Stress Induces a Transient, Calcineurin-Dependent Hypervirulent Phenotype in Mucorales Molds. MBio, 2020, 11, .	1.8	10
38	Chimeric Antigen Receptor T-cell Immunotherapy and Need for Prophylaxis for Invasive Mold Infections. Clinical Infectious Diseases, 2020, 71, 1802-1803.	2.9	11
39	Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia. MSphere, 2020, 5, .	1.3	18
40	A Novel Broad Allele-Specific TaqMan Real-Time PCR Method To Detect Triazole-Resistant Strains of Aspergillus fumigatus, Even with a Very Low Percentage of Triazole-Resistant Cells Mixed with Triazole-Susceptible Cells. Journal of Clinical Microbiology, 2019, 57, .	1.8	8
41	Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. Journal of Fungi (Basel, Switzerland), 2019, 5, 57.	1.5	37
42	On the Emergence of Candida auris: Climate Change, Azoles, Swamps, and Birds. MBio, 2019, 10, .	1.8	231
43	Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study. Open Forum Infectious Diseases, 2019, 6, ofz247.	0.4	24
44	Defining breakthrough invasive fungal infectionâ€“Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses, 2019, 62, 716-729.	1.8	129
45	Drosophila melanogaster as a model to study virulence and azole treatment of the emerging pathogen Candida auris. Journal of Antimicrobial Chemotherapy, 2019, 74, 1904-1910.	1.3	35
46	Therapeutic Challenges of Non- Aspergillus Invasive Mold Infections in Immunosuppressed Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	68
47	Checkpoint Inhibition and Infectious Diseases: A Good Thing?. Trends in Molecular Medicine, 2019, 25, 1080-1093.	3.5	37
48	Is Candida auris here to stay? An interview with Dimitrios Kontoyiannis. Future Microbiology, 2019, 14, 1083-1085.	1.0	0
49	Screening the in vitro susceptibility of posaconazole in clinical isolates of Candida spp. and Aspergillus spp. and analyzing the sequence of ERG11 or CYP51A in non-wild-type isolates from China. Diagnostic Microbiology and Infectious Disease, 2019, 95, 166-170.	0.8	2
50	Acute acalculous cholecystitis due to Fusarium species and review of the literature on fungal cholecystitis. Mycoses, 2019, 62, 847-853.	1.8	11
51	Live Monitoring and Analysis of Fungal Growth, Viability, and Mycelial Morphology Using the IncuCyte NeuroTrack Processing Module. MBio, 2019, 10, .	1.8	20
52	Culture-Documented Invasive Mold Infections at MD Anderson Cancer Center in Houston, Texas, Preâ€“ and Postâ€“Hurricane Harvey. Open Forum Infectious Diseases, 2019, 6, ofz138.	0.4	13
53	Nitroglycerin-Citrate-Ethanol Catheter Lock Solution Is Highly Effective for In Vitro Eradication of Candida auris Biofilm. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	10
54	A murine model of cutaneous aspergillosis for evaluation of biomaterialsâ€based local delivery therapies. Journal of Biomedical Materials Research - Part A, 2019, 107, 1867-1874.	2.1	5

#	Article	IF	Citations
55	Serum Levels of Crushed Posaconazole Delayed-Release Tablets. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	12
56	Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy. Clinical Infectious Diseases, 2019, 69, 1624-1627.	2.9	14
57	Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. Journal of Infection, 2019, 78, 484-490.	1.7	20
58	255. Breakthrough Mucormycosis (BT-MCR) on Antifungals Having Mucorales Activity Portrays Worse Prognosis compared with BT-MCR on Mold-Active Antifungals with no Mucorales Activity. Open Forum Infectious Diseases, 2019, 6, S142-S142.	0.4	2
59	Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	8
60	Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses, 2019, 62, 81-86.	1.8	31
61	Preexposure to Isavuconazole Increases the Virulence of Mucorales but Not Aspergillus fumigatus in a Drosophila melanogaster Infection Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	13
62	Baseline serum Aspergillus galactomannan index in patients with hematologic malignancy and culture-documented invasive pulmonary aspergillosis: is there a difference among Aspergillus species?. Medical Mycology, 2019, 57, 639-642.	0.3	1
63	Rhodotorula infection in haematological patient: Risk factors and outcome. Mycoses, 2019, 62, 223-229.	1.8	17
64	Hurricane-Associated Mold Exposures Among Patients at Risk for Invasive Mold Infections After Hurricane Harvey â€" Houston, Texas, 2017. Morbidity and Mortality Weekly Report, 2019, 68, 469-473.	9.0	24
65	Advances in the diagnosis and treatment of fungal infections of the CNS. Lancet Neurology, The, 2018, 17, 362-372.	4.9	93
66	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 757-763.	1.3	40
67	The Candida auris Alert: Facts and Perspectives. Journal of Infectious Diseases, 2018, 217, 516-520.	1.9	66
68	Fulminant Cryptococcus neoformans infection with fatal pericardial tamponade in a patient with chronic myelomonocytic leukaemia who was treated with ruxolitinib: Case report and review of fungal pericarditis. Mycoses, 2018, 61, 245-255.	1.8	22
69	How to prophylax against invasive fungal infections in adult <scp>ALL</scp>? An unmet need. Mycoses, 2018, 61, 646-649.	1.8	12
70	Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways. Clinical Infectious Diseases, 2018, 66, 140-148.	2.9	210
71	359. Baseline Serum Aspergillus Galactomannan Index Among Aspergillus Species in Hematologic Malignancies Patients With Invasive Pulmonary Aspergillosis. Open Forum Infectious Diseases, 2018, 5, S141-S141.	0.4	0
72	Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell, 2018, 5, 4-31.	1.4	158

#	Article	IF	Citations
73	Invasive fungal disease and cytomegalovirus infection: is there an association?. Current Opinion in Infectious Diseases, 2018, 31, 481-489.	1.3	47
74	Recent advances in the molecular diagnosis of mucormycosis. Expert Review of Molecular Diagnostics, 2018, 18, 845-854.	1.5	60
75	Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions. Clinical Infectious Diseases, 2018, 67, 1621-1630.	2.9	82
76	Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clinical Infectious Diseases, 2018, 67, 1610-1613.	2.9	73
77	Azole-Resistance in Aspergillus terreus and Related Species: An Emerging Problem or a Rare Phenomenon?. Frontiers in Microbiology, 2018, 9, 516.	1.5	66
78	Mixed mold pulmonary infections in haematological cancer patients in a tertiary care cancer centre. Mycoses, 2018, 61, 861-867.	1.8	14
79	Associations of inflammation with symptom burden in patients with acute myeloid leukemia. Psychoneuroendocrinology, 2018, 89, 203-208.	1.3	10
80	Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. Oncotarget, 2018, 9, 31244-31252.	0.8	17
81	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. American Journal of Hematology, 2017, 92, 119-120.	2.0	2
82	Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	66
83	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999â€“2015. Clinical Infectious Diseases, 2017, 65, 216-225.	2.9	50
84	Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Medicine, 2017, 9, 21.	3.6	80
85	Inherently Antimicrobial Biodegradable Polymers in Tissue Engineering. ACS Biomaterials Science and Engineering, 2017, 3, 1207-1220.	2.6	21
86	Breath-Based Diagnosis of Invasive Mucormycosis (IM). Open Forum Infectious Diseases, 2017, 4, S53-S54.	0.4	20
87	Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. Journal of Infectious Diseases, 2017, 216, S474-S483.	1.9	135
88	Invasive mold infections of the central nervous system in patients with hematologic cancer or stem cell transplantation (2000â€“2016): Uncommon, with improved survival but still deadly often. Journal of Infection, 2017, 75, 572-580.	1.7	30
89	<scp>PET</scp>â€positive lymphadenopathy in <scp>CLL</scp>â€”Not always <scp>R</scp>ichter transformation. American Journal of Hematology, 2017, 92, 405-406.	2.0	8
90	Antifungal Resistance: An Emerging Reality and A Global Challenge. Journal of Infectious Diseases, 2017, 216, S431-S435.	1.9	45

#	Article	IF	Citations
91	Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells. Frontiers in Immunology, 2017, 8, 1939.	2.2	52
92	Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. PLoS ONE, 2016, 11, e0150155.	1.1	46
93	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 2016, 63, e1-e60.	2.9	1,861
94	Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infectious Diseases, 2016, 16, 730.	1.3	98
95	The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196.	2.0	121
96	Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence ofRhizopus oryzae. Journal of Infectious Diseases, 2016, 214, 114-121.	1.9	30
97	Antifungal agents and liver toxicity: a complex interaction. Expert Review of Anti-Infective Therapy, 2016, 14, 765-776.	2.0	66
98	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	6.3	695
99	Mucormycoses. Infectious Disease Clinics of North America, 2016, 30, 143-163.	1.9	162
100	Aspergillus Cell Wall Melanin Blocks LC3-Associated Phagocytosis to Promote Pathogenicity. Cell Host and Microbe, 2016, 19, 79-90.	5.1	183
101	Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. Journal of Clinical Investigation, 2016, 126, 2280-2294.	3.9	84
102	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood, 2015, 126, 2790-2797.	0.6	46
103	UncommonCandidaSpecies Fungemia among Cancer Patients, Houston, Texas, USA. Emerging Infectious Diseases, 2015, 21, 1942-50.	2.0	87
104	Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS ONE, 2015, 10, e0139851.	1.1	47
105	Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiology, 2015, 10, 693-708.	1.0	40
106	Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae. Antimicrobial Agents and Chemotherapy, 2015, 59, 7830-7832.	1.4	9
107	T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial. Clinical Infectious Diseases, 2015, 60, 892-899.	2.9	369
108	The â€˜cephalosporin eraâ€™ of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opinion on Pharmacotherapy, 2015, 16, 1543-1558.	0.9	22

#	Article	IF	Citations
109	Combination Antifungal Therapy for Invasive Aspergillosis. Annals of Internal Medicine, 2015, 162, 81-89.	2.0	376
110	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). Medical Mycology, 2015, 53, 440-446.	0.3	79
111	Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests. Journal of Antimicrobial Chemotherapy, 2015, 70, 3100-3106.	1.3	13
112	1211A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients. Open Forum Infectious Diseases, 2014, 1, S37-S37.	0.4	4
113	Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity. Antimicrobial Agents and Chemotherapy, 2014, 58, 6993-6995.	1.4	90
114	Diagnosis and Treatment of Invasive Fungal Infections in the Cancer Patient: Recent Progress and Ongoing Questions. Clinical Infectious Diseases, 2014, 59, S356-S359.	2.9	17
115	1446Fungemia due to Uncommon Candida species in Patients with Cancer: Increasing Incidence, Frequent Resistance and High Mortality rates. Open Forum Infectious Diseases, 2014, 1, S380-S381.	0.4	0
116	Drug-ResistantCandida glabrataInfection in Cancer Patients. Emerging Infectious Diseases, 2014, 20, 1833-40.	2.0	127
117	Anidulafungin versus Caspofungin in a Mouse Model of Candidiasis Caused by Anidulafungin-Susceptible Candida parapsilosis Isolates with Different Degrees of Caspofungin Susceptibility. Antimicrobial Agents and Chemotherapy, 2014, 58, 229-236.	1.4	11
118	Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6767-6772.	1.4	42
119	A Long-Term Survivor of Disseminated Aspergillus and Mucorales Infection: An Instructive Case. Mycopathologia, 2014, 178, 465-470.	1.3	23
120	Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10660-10665.	3.3	171
121	Mold Infections of the Central Nervous System. New England Journal of Medicine, 2014, 371, 150-160.	13.9	157
122	Rational approach to pulmonary infiltrates inÂleukemia and transplantation. Best Practice and Research in Clinical Haematology, 2013, 26, 301-306.	0.7	13
123	Epidemiology and treatment of mucormycosis. Future Microbiology, 2013, 8, 1163-1175.	1.0	89
124	Tacrolimus Enhances the Potency of Posaconazole Against Rhizopus oryzae In Vitro and in an Experimental Model of Mucormycosis. Journal of Infectious Diseases, 2013, 207, 834-841.	1.9	55
125	Proangiogenic Growth Factors Potentiate In Situ Angiogenesis and Enhance Antifungal Drug Activity in Murine Invasive Aspergillosis. Journal of Infectious Diseases, 2013, 207, 1066-1074.	1.9	22
126	Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20â€year autopsy study. Mycoses, 2013, 56, 638-645.	1.8	198

#	Article	IF	Citations
127	Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production inAspergillus fumigatus. PeerJ, 2013, 1, e4.	0.9	63
128	Combination Therapy for Mucormycosis: Why, What, and How?. Clinical Infectious Diseases, 2012, 54, S73-S78.	2.9	139
129	Resistance to echinocandins comes at a cost. Virulence, 2012, 3, 95-97.	1.8	40
130	Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. Medical Mycology, 2012, 50, 543-548.	0.3	18
131	Antibiotic Exposure as a Risk Factor for Fluconazole-Resistant Candida Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2012, 56, 2518-2523.	1.4	137
132	Recent Advances in the Use ofDrosophila melanogasteras a Model to Study Immunopathogenesis of Medically Important Filamentous Fungi. International Journal of Microbiology, 2012, 2012, 1-10.	0.9	26
133	Pathogenesis of Mucormycosis. Clinical Infectious Diseases, 2012, 54, S16-S22.	2.9	541
134	The Deferasiroxâ€“AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. Journal of Antimicrobial Chemotherapy, 2012, 67, 715-722.	1.3	265
135	Epidemiology and Clinical Manifestations of Mucormycosis. Clinical Infectious Diseases, 2012, 54, S23-S34.	2.9	1,061
136	Invasive Mycoses: Strategies for Effective Management. American Journal of Medicine, 2012, 125, S25-S38.	0.6	68
137	The impact of azole resistance on aspergillosis guidelines. Annals of the New York Academy of Sciences, 2012, 1272, 15-22.	1.8	23
138	Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis?. Journal of Infection, 2012, 65, 262-268.	1.7	28
139	Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. Journal of Infection, 2012, 64, 68-75.	1.7	124
140	Fungal Infections in Transplant and Oncology Patients. Hematology/Oncology Clinics of North America, 2011, 25, 193-213.	0.9	27
141	Invasive Non-AspergillusMold Infections in Transplant Recipients, United States, 2001â€“2006. Emerging Infectious Diseases, 2011, 17, 1855-1864.	2.0	250
142	Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center. Cancer, 2011, 117, 3424-3433.	2.0	58
143	Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence ofCandidaandAspergillusspecies. Virulence, 2011, 2, 280-295.	1.8	31
144	Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. Journal of Infectious Diseases, 2011, 204, 626-635.	1.9	124

#	Article	IF	Citations
145	Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998â€“2009. Journal of Infection, 2010, 60, 331-337.	1.7	145
146	Generation of IL-23 Producing Dendritic Cells (DCs) by Airborne Fungi Regulates Fungal Pathogenicity via the Induction of TH-17 Responses. PLoS ONE, 2010, 5, e12955.	1.1	105
147	Antifungal Activity of Colistin against Mucorales Species In Vitro and in a Murine Model of Rhizopus oryzae Pulmonary Infection. Antimicrobial Agents and Chemotherapy, 2010, 54, 484-490.	1.4	56
148	Is it Safe to Proceed with Stem Cell Transplant in Cancer Patients Treated for Cryptococcal Infection? A Focus on Recent IDSA Cryptococcal Guidelines. Clinical Infectious Diseases, 2010, 50, 1687-1689.	2.9	5
149	Interstrain variability in the virulence ofAspergillus fumigatusandAspergillus terreusin aToll-deficientDrosophilafly model of invasive aspergillosis. Medical Mycology, 2010, 48, 310-317.	0.3	32
150	Prospective Surveillance for Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients, 2001â€“2006: Overview of the Transplantâ€Associated Infection Surveillance Network (TRANSNET) Database. Clinical Infectious Diseases, 2010, 50, 1091-1100.	2.9	1,194
151	Invasive Fungal Infections among Organ Transplant Recipients: Results of the Transplantâ€Associated Infection Surveillance Network (TRANSNET). Clinical Infectious Diseases, 2010, 50, 1101-1111.	2.9	1,281
152	Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Medical Mycology, 2010, 48, 1-9.	0.3	17
153	Molecular Identification of Aspergillus Species Collected for the Transplant-Associated Infection Surveillance Network. Journal of Clinical Microbiology, 2009, 47, 3138-3141.	1.8	266
154	Echinocandinâ€Based Initial Therapy in Fungemic Patients with Cancer: A Focus on Recent Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 49, 638-639.	2.9	21
155	Increased Virulence of Zygomycetes Organisms Following Exposure to Voriconazole: A Study Involving Fly and Murine Models of Zygomycosis. Journal of Infectious Diseases, 2009, 199, 1399-1406.	1.9	117
156	Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood, 2009, 114, 5393-5399.	0.6	99
157	The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. Medical Mycology, 2008, 46, 23-29.	0.3	60
158	Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clinical Infectious Diseases, 2008, 47, 674-683.	2.9	368
159	Delaying Amphotericin Bâ€“Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis. Clinical Infectious Diseases, 2008, 47, 503-509.	2.9	639
160	Caspofunginâ€Mediated Î²â€Glucan Unmasking and Enhancement of Human Polymorphonuclear Neutrophil Activity againstAspergillusand Nonâ€AspergillusHyphae. Journal of Infectious Diseases, 2008, 198, 186-192.	1.9	174
161	Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9367-9372.	3.3	123
162	Molecular Typing of Aspergillus terreus Isolates Collected in Houston, Texas, and Innsbruck, Austria: Evidence of Great Genetic Diversity. Journal of Clinical Microbiology, 2007, 45, 2686-2690.	1.8	49

#	Article	IF	Citations
163	Increased Culture Recovery of Zygomycetes Under Physiologic Temperature Conditions. American Journal of Clinical Pathology, 2007, 127, 208-212.	0.4	48
164	Caspofungin as Primary Antifungal Prophylaxis in Stem Cell Transplant Recipients. Pharmacotherapy, 2007, 27, 1644-1650.	1.2	69
165	Recombinant interferon Î³1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer, 2006, 106, 2664-2671.	2.0	71
166	Pentamidine Is Active in a Neutropenic Murine Model of Acute Invasive Pulmonary Fusariosis. Antimicrobial Agents and Chemotherapy, 2006, 50, 294-297.	1.4	10
167	Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases. Clinical Infectious Diseases, 2006, 42, e61-e65.	2.9	553
168	Clinical Issues Regarding Relapsing Aspergillosis and the Efficacy of Secondary Antifungal Prophylaxis in Patients with Hematological Malignancies. Clinical Infectious Diseases, 2006, 42, 1584-1591.	2.9	82
169	Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica, 2006, 91, 986-9.	1.7	357
170	Aspergillus Hyphae in Infected Tissue: Evidence of Physiologic Adaptation and Effect on Culture Recovery. Journal of Clinical Microbiology, 2005, 43, 382-386.	1.8	45
171	AspergillusSusceptibility Testing in Patients with Cancer and Invasive Aspergillosis: Difficulties in Establishing Correlation Between In Vitro Susceptibility Data and the Outcome of Initial Amphotericin B Therapy. Pharmacotherapy, 2005, 25, 1174-1180.	1.2	36
172	Tollâ€Deficient Drosophila Flies as a Fast, Highâ€Throughput Model for the Study of Antifungal Drug Efficacy against Invasive Aspergillosis and Aspergillus Virulence. Journal of Infectious Diseases, 2005, 191, 1188-1195.	1.9	84
173	Frequency and Species Distribution of Gliotoxin-Producing Aspergillus Isolates Recovered from Patients at a Tertiary-Care Cancer Center. Journal of Clinical Microbiology, 2005, 43, 6120-6122.	1.8	99
174	Zygomycosis in a Tertiaryâ€Care Cancer Center in the Era of Aspergillusâ€Active Antifungal Therapy: A Caseâ€Control Observational Study of 27 Recent Cases. Journal of Infectious Diseases, 2005, 191, 1350-1360.	1.9	659
175	Increased frequency of non-fumigatus Aspergillus species in amphotericin Bâ€“ or triazoleâ€“pre-exposed cancer patients with positive cultures for aspergilli. Diagnostic Microbiology and Infectious Disease, 2005, 52, 15-20.	0.8	78
176	Infections Due to Aspergillus terreus: A Multicenter Retrospective Analysis of 83 Cases. Clinical Infectious Diseases, 2004, 39, 192-198.	2.9	276
177	Toward more effective antifungal therapy: the prospects of combination therapy. British Journal of Haematology, 2004, 126, 165-175.	1.2	75
178	The significance of isolation of saprophytic molds from the lower respiratory tract in patients with cancer. Cancer, 2004, 100, 165-172.	2.0	32
179	Aspergillus terreus. Cancer, 2004, 101, 1594-1600.	2.0	120
180	Impact of high-dose granulocyte transfusions in patients with cancer with candidemia. Cancer, 2004, 101, 2859-2865.	2.0	102

#	Article	IF	Citations
181	Glucocorticoids and invasive fungal infections. Lancet, The, 2003, 362, 1828-1838.	6.3	556
182	Diagnosis of Invasive Septate Mold Infections. American Journal of Clinical Pathology, 2003, 119, 854-858.	0.4	208
183	Pentamidine Is Active In Vitro against Fusarium Species. Antimicrobial Agents and Chemotherapy, 2003, 47, 3252-3259.	1.4	25
184	Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. American Journal of Clinical Pathology, 2003, 119, 854-8.	0.4	82
185	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. Transplant Infectious Disease, 2001, 3, 29-33.	0.7	5
186	Progressive Disseminated Aspergillosis in a Bone Marrow Transplant Recipient: Response with a High-Dose Lipid Formulation of Amphotericin B. Clinical Infectious Diseases, 2001, 32, e94-e96.	2.9	13
187	Effect of fluconazole on agar invasion by Candida albicans. Journal of Medical Microbiology, 2001, 50, 78-82.	0.7	17
188	Zygomycosis in the 1990s in a Tertiary-Care Cancer Center. Clinical Infectious Diseases, 2000, 30, 851-856.	2.9	484
189	Overexpression of Erg11p by the Regulatable GAL1 Promoter Confers Fluconazole Resistance in Saccharomyces cerevisiae. Antimicrobial Agents and Chemotherapy, 1999, 43, 2798-2800.	1.4	56
190	Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections. Journal of Infectious Diseases, 1995, 172, 599-602.	1.9	139